Public Comment-alt model for payment for Part B drugs
“Buy and Bill” was designed at a time when Part B drugs were relatively inexpensive. It is not optimized for the current health care system, where Part B...
“Buy and Bill” was designed at a time when Part B drugs were relatively inexpensive. It is not optimized for the current health care system, where Part B...
The Drug Pricing Lab at Memorial Sloan Kettering Cancer Center focuses on the development of rational approaches to drug pricing and health insurance coverage that encourage innovation while...
It is viewed as a potential incentive to prescribe more expensive drugs when cheaper alternatives exist, as 6% of a high price is more than 6% of a...
Partner with Verdant for rigorous, objective economic analysis.